Decoy Therapeutics Inc (DCOY)

$7.62 +0.13 (1.74%)
Market Cap 4.05M
Revenue (ttm) 0.00
Net Income (ttm) -5.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 20,900
Avg Vol 227,791
Day's Range N/A - N/A
Shares Out 532,000.00
Stochastic %K 46%
Beta 0.30
Analysts Sell
Price Target $30.01

Company Profile

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio o...

Industry: Biotechnology
Sector: Healthcare
Website: decoytx.com
Address:
One Broadway, 14th Floor, Cambridge, United States
frankyboyz
frankyboyz Mar. 11 at 2:38 PM
watching close $DCOY on its 7 dips, 7.50/7 has to hold , so pretty close. this is a recent rs ticker with 500k float and had news today. https://finviz.com/news/336403/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform Lets see if goes a second time chartish could have potentially room
0 · Reply
MooonNuggets
MooonNuggets Mar. 11 at 2:18 PM
$DXST LOADED STILL $DCOY Grabbed some at 7.70 $SGN loaded more $WORX they're trying for 0.13 I will load there $HIMS - LOADED $30 calls yesterday at $22 booming
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 1:06 PM
$DCOY Quick highlights from the article • Decoy announced a strategic collaboration with Quantori, supported by funding from Google Cloud. • They are building a Google Cloud–native AI platform for peptide drug design and molecular simulations. • The system is expected to increase computational peptide-design throughput by 25×–100×, allowing faster discovery of antiviral drug candidates.  • It will integrate: • protein folding models • molecular dynamics simulations • machine learning and generative AI • Decoy’s proprietary IMP³ACT design-build-test-learn engine.
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 1:04 PM
$DCOY https://www.prnewswire.com/news-releases/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform-302710286.html?utm_source=chatgpt.com
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 12:55 PM
$DCOY Key Announcement: The collaboration will build a cloud-native platform that combines: • AI-driven peptide drug design • Molecular simulation tools • High-performance cloud computing • Integrated data pipelines for drug discovery The platform is intended to help Decoy rapidly design and optimize antiviral peptide therapeutics. Why this matters The goal is to speed up early-stage drug discovery by allowing researchers to: • Simulate molecular interactions before laboratory testing • Design peptides with higher binding efficiency to viral targets • Run large-scale computational screening using cloud computing rather than lab experiments In simple terms: Instead of testing thousands of molecules in a lab, they can use AI to narrow the candidates first, saving time and cost. Today’s news is about building an AI-powered drug discovery platform on Google Cloud with Quantori, aimed at speeding up Decoy’s antiviral peptide development pipeline.
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 11 at 12:32 PM
$DCOY - Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 11 at 12:32 PM
$DCOY Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
0 · Reply
StormTitan
StormTitan Mar. 11 at 12:30 PM
$DCOY
0 · Reply
Denker327
Denker327 Mar. 9 at 9:51 PM
$DCOY That float! 🤯
0 · Reply
TwongStocks
TwongStocks Mar. 9 at 8:19 PM
Today's reverse split results. 2 of 5 closed green. $ADTX 1 for 8 Previous close $0..4656, $3.7248 split-adjusted Intraday high $4.36 Today's close $3.47 🔴Down 6.84% $BHAT 1 for 50 Previous close $0.0348, $1.74 split-adjusted Intraday high $1.89 Today's close $1.72 🔴Down 1.15% $DCOY 1 for 12 Previous close $0.6318, $7.5816 split-adjusted Intraday high $8.68 Today's close $8.6101 🟢Up 13.57% $DTCK 1 for 20 Previous close $0.0715, $1.43 split-adjusted Intraday high $3.39 Today's close $2.49 🟢Up 74.13% $RVPH 1 for 20 Previous close $0.1786, $3.572 split-adjusted Premarket high $3.57 Today's close $2.88 🔴Down 19.37%
0 · Reply
Latest News on DCOY
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Mar 11, 2026, 8:30 AM EDT - 4 days ago

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Mar 5, 2026, 8:30 AM EST - 10 days ago

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Feb 11, 2026, 9:00 AM EST - 4 weeks ago

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 5 weeks ago

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Feb 4, 2026, 9:02 AM EST - 5 weeks ago

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Jan 13, 2026, 8:15 AM EST - 2 months ago

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Jan 7, 2026, 8:45 AM EST - 2 months ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 3 months ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 3 months ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 3 months ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 4 months ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 4 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 4 months ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 5 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 6 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 8 months ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 8 months ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 1 year ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 1 year ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 3 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 3 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 3 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Nov 3, 2022, 9:57 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 27, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 19, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

frankyboyz
frankyboyz Mar. 11 at 2:38 PM
watching close $DCOY on its 7 dips, 7.50/7 has to hold , so pretty close. this is a recent rs ticker with 500k float and had news today. https://finviz.com/news/336403/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform Lets see if goes a second time chartish could have potentially room
0 · Reply
MooonNuggets
MooonNuggets Mar. 11 at 2:18 PM
$DXST LOADED STILL $DCOY Grabbed some at 7.70 $SGN loaded more $WORX they're trying for 0.13 I will load there $HIMS - LOADED $30 calls yesterday at $22 booming
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 1:06 PM
$DCOY Quick highlights from the article • Decoy announced a strategic collaboration with Quantori, supported by funding from Google Cloud. • They are building a Google Cloud–native AI platform for peptide drug design and molecular simulations. • The system is expected to increase computational peptide-design throughput by 25×–100×, allowing faster discovery of antiviral drug candidates.  • It will integrate: • protein folding models • molecular dynamics simulations • machine learning and generative AI • Decoy’s proprietary IMP³ACT design-build-test-learn engine.
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 1:04 PM
$DCOY https://www.prnewswire.com/news-releases/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform-302710286.html?utm_source=chatgpt.com
0 · Reply
Rebel2727
Rebel2727 Mar. 11 at 12:55 PM
$DCOY Key Announcement: The collaboration will build a cloud-native platform that combines: • AI-driven peptide drug design • Molecular simulation tools • High-performance cloud computing • Integrated data pipelines for drug discovery The platform is intended to help Decoy rapidly design and optimize antiviral peptide therapeutics. Why this matters The goal is to speed up early-stage drug discovery by allowing researchers to: • Simulate molecular interactions before laboratory testing • Design peptides with higher binding efficiency to viral targets • Run large-scale computational screening using cloud computing rather than lab experiments In simple terms: Instead of testing thousands of molecules in a lab, they can use AI to narrow the candidates first, saving time and cost. Today’s news is about building an AI-powered drug discovery platform on Google Cloud with Quantori, aimed at speeding up Decoy’s antiviral peptide development pipeline.
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 11 at 12:32 PM
$DCOY - Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 11 at 12:32 PM
$DCOY Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
0 · Reply
StormTitan
StormTitan Mar. 11 at 12:30 PM
$DCOY
0 · Reply
Denker327
Denker327 Mar. 9 at 9:51 PM
$DCOY That float! 🤯
0 · Reply
TwongStocks
TwongStocks Mar. 9 at 8:19 PM
Today's reverse split results. 2 of 5 closed green. $ADTX 1 for 8 Previous close $0..4656, $3.7248 split-adjusted Intraday high $4.36 Today's close $3.47 🔴Down 6.84% $BHAT 1 for 50 Previous close $0.0348, $1.74 split-adjusted Intraday high $1.89 Today's close $1.72 🔴Down 1.15% $DCOY 1 for 12 Previous close $0.6318, $7.5816 split-adjusted Intraday high $8.68 Today's close $8.6101 🟢Up 13.57% $DTCK 1 for 20 Previous close $0.0715, $1.43 split-adjusted Intraday high $3.39 Today's close $2.49 🟢Up 74.13% $RVPH 1 for 20 Previous close $0.1786, $3.572 split-adjusted Premarket high $3.57 Today's close $2.88 🔴Down 19.37%
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 9 at 6:51 PM
$DCOY
0 · Reply
Travelling
Travelling Mar. 9 at 5:49 PM
$OLOX buying to hold, also $DCOY watching $ADTX $SVRN
0 · Reply
TwongStocks
TwongStocks Mar. 9 at 11:59 AM
$ADTX $BHAT $DCOY $DTCK $RVPH All five with reverse splits today. Trading is scheduled to resume at 9:00am ET, with the RS in effect. RS details for each company are in the quoted post.
0 · Reply
VintageVibes
VintageVibes Mar. 9 at 5:31 AM
$DCOY 1-for-12 Reverse Stock Split: Effective as of 5:00 p.m. ET on March 6, 2026, Decoy implemented a 1-for-12 reverse stock split. Split-adjusted trading begins today, March 9
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 9 at 3:02 AM
🌅 Watchlist part 2 ✅ $DLXY low $1.0 support, if above $1.40, have potential to $1.70 / $1.80 ✅ $ADTX 1/8 reverse split (RS), new price ~ $3.68 ✅ $BHAT 1/50 RS, new price ~ $1.50 ✅ $DCOY 1/12 RS, new price ~ $7.56 ✅ $DTCK 1/20 RS, new price ~ $1.40 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
TwongStocks
TwongStocks Mar. 6 at 9:04 PM
I am aware of five NASDAQ reverse splits scheduled on Monday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. $ADTX 1 for 8. Will reduce outstanding shares from approx 4.14m to approx 518k. $BHAT 1 for 50. Will reduce outstanding shares from approx 154.91m to approx 3.1m. $DCOY 1 for 12. Will reduce outstanding shares from approx 6.38m to approx 532k. $DTCK 1 for 20. Will reduce outstanding Class A shares from approx 10.86m to approx 543k and Class B shares from approx 16.51m to approx 826k. $RVPH 1 for 20. Will reduce outstanding shares from approx 116.85m to approx 5.84m.
4 · Reply
TwongStocks
TwongStocks Mar. 5 at 8:09 PM
$DCOY Equity Corporate Actions Alert #2026 - 135 Information Regarding the Reverse Stock Split and CUSIP Number Change for Decoy Therapeutics Inc. (DCOY) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-135 Decoy Therapeutics Inc. (DCOY) will effect a one-for-twelve (1-12) reverse split of its Common Stock. The reverse stock split will become effective on Monday, March 9, 2026. In conjunction with the reverse split, the CUSIP number will change to 79400X602.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 1:24 PM
$DCOY Current Stock Price: $0.69
0 · Reply
Brokechump
Brokechump Feb. 25 at 8:02 PM
$DCOY Closed mine. To far gone for me. Good luck to who stays.
0 · Reply
Brokechump
Brokechump Feb. 25 at 7:59 PM
$DCOY They RS vote passed. Filing is out. Not sure when it will be carried out. I located it on Fintel
0 · Reply
98till
98till Feb. 25 at 6:42 PM
$DCOY @MS_Tammy still here?
1 · Reply